Home Tags Pyrrolobenzodiazepine

Tag: pyrrolobenzodiazepine

Featured Image: Close-up cityscape of Lugano city waterfront along Lugano Lake. Facades of historic houses in front of alp mountains. Courtesy: © 2017. Fotolia. Used with permission.

15th ICML: Camidanlumab Tesirine Shows High Overall Response Rate in R/R...

During the International Conference on Malignant Lymphoma (ICML), one of the must-attend events for the scientific community involved in the study and treatment of...

First Patient Dosed in Phase Ib Clinical Trial of Camidanlumab Tesirine...

A first patient has been dosed in Phase Ib clinical trial of camidanlumab tesirine, also know ADCT-301, a proprietary antibody-drug conjugate or ADC being...

Study Evaluates Pyrrolobenzodiazepine (PBD)-dimers Containing Disulfide-based Prodrugs as Payloads for Antibody-Drug...

A number of cytotoxic pyrrolobenzodiazepine (PBD) monomers containing various disulfide-based prodrugs were evaluated for their ability to undergo activation (disulfide cleavage) in vitro in...

Anti-CLL-1 ADC May Offer Effective and Safe Treatment Options for Patients...

Over the last 40 years treatment of acute myeloid leukemia or AML has not significantly changed.Today, the standard of care for AML is treatment...
Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

Interim Phase I Data from Camidanlumab Tesirine (ADCT-301) Shows Encouraging Preliminary...

Clinical data from two ongoing Phase I clinical trials evaluating camidanlumab tesirine, also known as ADCT-301* or "Cami-T", in important subtypes of lymphoma and...

First Clinical Data from ADCT-402 Demonstrates Encouraging Antitumor Activity in r/r...

The first clinical data from an ongoing Phase I clinical trial evaluating ADCT-402 for the treatment of relapsed or refractory non-Hodgkin’s lymphoma has been...

U.S. FDA Lifts Clinical Hold Phase I Trials of Vadastuximab Talirine

The U.S. Food and Drug Administration (FDA) confirmed today that it has lifted the clinical hold on phase 1 trials of vadastuximab talirine (SGN-CD33A;...

Novel Cancer Therapeutics Drive Therapy Market

An increased need for better cancer treatment continues to boost the global cancer biological therapy market. According to a report published by Global Market...

Phase I Trial of SGN-CD352A in Relapsed or Refractory Multiple Myeloma...

This week the first patient enrolled in a multi-center phase I clinical trial of SGN-CD352A for the treatment of patients with relapsed or refractory...

Cancer Research Technology, University of Copenhagen and ADC Therapeutics Sign Agreement

Cancer Research Technology UK and the University of Copenhagen announced their agreement with Switzerland-based ADC-Therapeutics SA  to develop novel antibody therapeutics for the treatment...

FEATURED RESOURCES